Patents Examined by Catherine Joyce
  • Modulators of the interaction between Arp2/3 and cortactin or HS-1
    Patent number: 7192702
    Abstract: The invention relates to methods for screening compounds for their ability to modulate actin polymerization. The invention is also related to compounds which modulate actin polymerization. More specifically, the invention is related to methods of screening compounds which modulate the interaction of cortactin or HS-1 with Arp2/3. The invention is also related to compounds which modulate the interaction of cortactin of HS1 with Arp2/3. Also provided are mutants of cortactin with decreased ability to interact with Arp2/3.
    Type: Grant
    Filed: August 29, 2001
    Date of Patent: March 20, 2007
    Assignee: University of Maryland, Baltimore
    Inventors: Xi Zhan, Takehito Uruno
  • Use of insulin-like growth factor binding protein 3 (IGF-BP3) for inhibition of tumor growth
    Patent number: 7166288
    Abstract: A method of inhibiting proliferation of cells associated with a tumor in a subject which comprises administering to the subject a tumor cell proliferation amount of IGF-BP3, thereby inhibiting proliferation of the cells. An improved surgical method which comprises surgically resecting a tumor from a subject and administering to the subject an amount of a protein effective to inhibit metastasis of any tumor cells released in the subject's blood circulation during the surgical resection of the tumor.
    Type: Grant
    Filed: February 13, 2003
    Date of Patent: January 23, 2007
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Irena Kirman, Richard L. Whelan
  • Serpentine transmembrane antigens expressed in human cancers and uses thereof
    Patent number: 7166714
    Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigens of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.
    Type: Grant
    Filed: December 31, 2003
    Date of Patent: January 23, 2007
    Assignee: Agensys, Inc.
    Inventors: Daniel E. H. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran, Stephen C. Mitchell
  • HLA-A24 binding peptides of enhancer of zeste homolog 2
    Patent number: 7160545
    Abstract: A cancer antigen peptide comprising an amino acid sequence shown in SEQ ID NO: 1 or 2, or a derivative thereof having the functionally equivalent property is provided. The provided cancer antigen peptide is a partial peptide derived from enhancer of zeste homolog 2, which is capable of binding to HLA-A24 antigen and is recognized by cytotoxic T lymphocytes. The cancer antigen peptide of the invention is useful for treatment and prevention of prostate cancer.
    Type: Grant
    Filed: August 23, 2005
    Date of Patent: January 9, 2007
    Assignee: Green Peptide Co., Ltd.
    Inventors: Kyogo Itoh, Mamoru Harada